bluebird bio (BLUE) PT Raised 10% at Jefferies Following 'Impressive' Initial BCMA CAR-T Ph1 Data

December 1, 2016 7:47 AM EST Send to a Friend
Jefferies analyst Gena Wang reiterated a Buy rating and lifted her price target on bluebird bio (NASDAQ: BLUE) to $88.00 ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login